LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Amphastar Pharmaceuticals Inc

Cerrado

SectorSanidad

29.07 -0.68

Resumen

Variación precio

24h

Actual

Mínimo

28.83

Máximo

29.34

Métricas clave

By Trading Economics

Ingresos

5.7M

31M

Ventas

3.9M

174M

P/B

Media del Sector

11.468

35.733

Margen de beneficios

17.791

Empleados

2,028

EBITDA

9.5M

62M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+8.77% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

415M

1.4B

Apertura anterior

29.75

Cierre anterior

29.07

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

173 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Amphastar Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 sept 2025, 23:37 UTC

Acciones populares

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 sept 2025, 20:41 UTC

Ganancias

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 sept 2025, 20:30 UTC

Ganancias

GameStop 2Q Sales, Profit Rise

9 sept 2025, 23:19 UTC

Charlas de Mercado

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 sept 2025, 21:35 UTC

Ganancias

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 21:32 UTC

Ganancias

Oracle's Backlog Swells With Big Customer Deals -- Update

9 sept 2025, 21:02 UTC

Adquisiciones, fusiones, absorciones

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 sept 2025, 20:33 UTC

Ganancias

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 sept 2025, 20:26 UTC

Ganancias

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 20:23 UTC

Ganancias

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 20:12 UTC

Ganancias

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 sept 2025, 20:10 UTC

Ganancias

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 sept 2025, 20:10 UTC

Ganancias

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 sept 2025, 20:09 UTC

Ganancias

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 sept 2025, 20:09 UTC

Ganancias

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 sept 2025, 20:08 UTC

Ganancias

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 sept 2025, 20:07 UTC

Ganancias

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 sept 2025, 20:06 UTC

Ganancias

Oracle 1Q Software Revenue $5.72B >ORCL

9 sept 2025, 20:06 UTC

Ganancias

Synopsys 3Q Adj EPS $3.39 >SNPS

9 sept 2025, 20:06 UTC

Ganancias

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Rev $14.93B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q EPS $1.01 >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Synopsys 3Q EPS $1.50 >SNPS

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Services Revenue $1.35B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Adj EPS $1.47 >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Hardware Revenue $670M >ORCL

Comparación entre iguales

Cambio de precio

Amphastar Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

8.77% repunte

Estimación a 12 Meses

Media 32 USD  8.77%

Máximo 36 USD

Mínimo 25 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amphastar Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

2

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

23.91 / 25.04Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

173 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
help-icon Live chat